Hemophilia A (factor VIII [FVIII] deficiency) and hemophilia B (factor IX [FIX] deficiency) are the X-linked recessive bleeding disorders that clinically manifest with recurrent bleeding, predominantly into muscles and joints. In its severe presentation, when factor activity is less than 1% of normal, hemophilia presents with spontaneous musculoskeletal bleeds and may progress to debilitating chronic arthropathy. Management of hemophilia has changed profoundly in the past decades. From on-demand to prophylactic factor concentrate replacement, the treatment goal shifted from controlling bleeds to preventing bleeds and improving quality of life. In this new scenario, gene therapy has arisen as a paradigm-changing therapeutic option, a one-time treatment with the potential to achieve sustained coagulation FVIII or FIX expression even within the normal range. This review discusses the critical impact of adeno-associated virus (AAV) gene transfer in hemophilia care, including the recent clinical outcomes, changes in disease perceptions, and its treatment burden. We also discuss the challenging scenario of the AAV-directed immune response in the clinical setting and potential strategies to improve the long-lasting efficacy of hemophilia gene therapy efficacy.
SrivastavaASantagostinoEDougallAKitchenSSutherlandMPipeSWCarcaoMMahlanguJRagniMVWindygaJLlinasAGoddardNJMohanRPoonnoosePMFeldmanBMLewisSZvan den BergHMPierceGF, WFH Guidelines for the Management of Hemophilia Panelists and Co-authors. WFH guidelines for the management of hemophilia, 3rd edition.Haemophilia2020;26:1–158
NathwaniACTuddenhamEGRangarajanSRosalesCMcIntoshJLinchDCChowdaryPRiddellAPieAJHarringtonCO’BeirneJSmithKPasiJGladerBRustagiPNgCYKayMAZhouJSpenceYMortonCLAllayJColemanJSleepSCunninghamJMSrivastavaDBasner-TschakarjanEMingozziFHighKAGrayJTReissUMNienhuisAWDavidoffAM.Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.N Engl J Med2011;365:2357–65
5.
RangarajanSWalshLLesterWPerryDMadanBLaffanMYuHVettermannCPierceGFWongWYPasiKJ.AAV5-factor VIII gene transfer in severe hemophilia A.N Engl J Med2017;377:2519–30
6.
GeorgeLAMonahanPEEysterMESullivanSKRagniMVCroteauSERaskoJEJRechtMSamelson-JonesBJMacDougallAJaworskiKNobleRCurranMKurandaKMingozziFChangTReapeKZAnguelaXMHighKA.Multiyear factor VIII expression after AAV gene transfer for hemophilia A.N Engl J Med2021;385:1961–73
7.
PasiKJLaffanMRangarajanSRobinsonTMMitchellNLesterWSymingtonEMadanBYangXKimBPierceGFWongWY.Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.Haemophilia2021;27: 947–56
GeorgeLASullivanSKGiermaszARaskoJEJSamelson-JonesBJDucoreJCukerASullivanLMMajumdarSTeitelJMcGuinnCERagniMVLukAYHuiDWrightJFChenYLiuYWachtelKWintersATiefenbacherSArrudaVRvan der LooJCMZelenaiaOTakefmanDCarrMECoutoLBAnguelaXMHighKA.Hemophilia B gene therapy with a high-specific-activity factor IX variant.N Engl J Med2017;377:2215–27
10.
MiesbachWMeijerKCoppensMKampmannPKlamrothRSchutgensRTangelderMCastamanGSchwäbleJBonigHSeifriedECattaneoFMeyerCLeebeekFWG. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.Blood2018;131:1022–31
11.
KonkleBAWalshCEEscobarMAJosephsonNCYoungGvon DrygalskiAMcPheeSWJSamulskiRJBilicIde la RosaMReipertBMRottensteinerHScheiflingerFChapinJCEwensteinBMonahanPE.BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.Blood2021;137:763–74
12.
ChowdaryPShapiroSMakrisMEvansGBoyceSTalksKDolanGReissUPhillipsMRiddellAPeraltaMRQuayeMPatchDWTuddenhamEDaneAWatisséeMLongANathwaniA.Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B.N Engl J Med2022;387:237–47
13.
IorioASkinnerMWClearfieldEMessnerDPierceGFWitkopMTunisS, coreHEM panel. Core outcome set for gene therapy in haemophilia: results of the coreHEM multistakeholder project.Haemophilia2018;24:e167–72
14.
SidonioRFJrPipeSWCallaghanMUValentinoLAMonahanPECroteauSE.Discussing investigational AAV gene therapy with hemophilia patients: a guide.Blood Rev2021;47:100759
15.
BarrowcliffeTWRautSHubbardAR.Discrepancies in potency assessment of recombinant FVIII concentrates.Haemophilia1998;4:634–40
16.
HubbardARWellerLJBevanSA.A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates.Br J Haematol2002;117:247–8
17.
MikaelssonMOswaldssonUSandbergH.Influence of phospholipids on the assessment of factor VIII activity.Haemophilia1998;4:646–50
RosenSTiefenbacherSRobinsonMHuangMSrimaniJMackenzieDChristiansonTPasiKJRangarajanSSymingtonEGiermaszAPierceGFKimBZoogSJVettermannC.Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy.Blood2020;136:2524–34
SimioniPTormeneDTogninGGavassoSBulatoCIacobelliNPFinnJDSpieziaLRaduCArrudaVR.X-linked thrombophilia with a mutant factor IX (factor IX Padua).N Engl J Med2009;361:1671–5
22.
BattyPLillicrapD.Gene therapy for hemophilia: current status and laboratory consequences.Int J Lab Hematol2021;43:117–23
23.
FoleyJHShehuERiddellAGrayEGoodaleAYuIMVerhoefDLittleJAShattockDKitchenSChowdaryPCorbauRNathwaniAC.Differences in wild type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies.Blood Adv. Epub ahead of print 15 July 2022. DOI: 10.1182/bloodadvances.2022007435
BakeerNDoverSBabynPFeldmanBMvon DrygalskiADoriaASIgnasDMAbadABaileyCBeggsIChangEYDunnAFunkSGibikoteSGoddardNHilliardPKeshavaSNKruse-JarresRLiYLobetSManco-JohnsonMMartinoliCO’DonnellJSPapakonstantinouOPergantouHPoonnoosePQuerolFSrivastavaASteinerBStrikeKTimmerMTyrrellPNVidarssonLBlanchetteVS.Musculoskeletal ultrasound in hemophilia: results and recommendations from a global survey and consensus meeting.Res Pract Thromb Haemost2021;5:e12531
27.
Manco-JohnsonMJAbshireTCShapiroADRiskeBHackerMRKilcoyneRIngramJDManco-JohnsonMLFunkSJacobsonLValentinoLAHootsWKBuchananGRDiMicheleDRechtMBrownDLeissingerCBleakSCohenAMathewPMatsunagaAMedeirosDNugentDThomasGAThompsonAAMcRedmondKSoucieJMAustinHEvattBL.Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.N Engl J Med2007;357:535–44
28.
WojdasiewiczPPoniatowskiLANaumanPMandatTParadowska-GoryckaARomanowska-ProchnickaKSzukiewiczDKotelaAKubaszewskiLKotelaIKurkowska-JastrzebskaIGasikR.Cytokines in the pathogenesis of hemophilic arthropathy.Cytokine Growth Factor Rev2018;39:71–91
29.
Den UijlIEMauser BunschotenEPRoosendaalGSchutgensREBiesmaDHGrobbeeDEFischerK.Clinical severity of haemophilia A: does the classification of the 1950s still stand.Haemophilia2011;17:849–53
30.
TreedeRDRiefWBarkeAAzizQBennettMIBenolielRCohenMEversSFinnerupNBFirstMBGiamberardinoMAKaasaSKorwisiBKosekELavand’hommePNicholasMPerrotSScholzJSchugSSmithBHSvenssonPVlaeyenJWSWangSJ.Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11).Pain2019;160:19–27
31.
HumphriesTJKesslerCM.Managing chronic pain in adults with haemophilia: current status and call to action.Haemophilia2015;21:41–51
32.
HolsteinKKlamrothRRichardsMCarvalhoMPerez-GarridoRGringeriA, European Haemophilia Therapy Standardization B. Pain management in patients with haemophilia: a European survey.Haemophilia2012;18:743–52
33.
Manco-JohnsonMJLundinBFunkSPeterfyCRaunigDWerkMKemptonCLRedingMTGoranovSGerchevaLRusenLUscatescuVPierdominiciMEngelenSPocoskiJWalkerDHongW.Effect of late prophylaxis in hemophilia on joint status: a randomized trial.J Thromb Haemost2017;15:2115–24
34.
KiialainenANiggliMKemptonCLCastamanGChangTPaz-PrielIAdamkewiczJILevyGG.Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.Haemophilia2022;28:1033–43
35.
Basic documents: forty-ninth edition (including amendments adopted up to 31 May 2019). Geneva: World Health Organization, 2020
36.
QuinnJDelaneyKAWongWYMiesbachWBullingerM.Psychometric validation of the haemo-QOL-A in participants with hemophilia A treated with gene therapy.Patient Relat Outcome Meas2022;13:169–80
BucknerTWBattKQuonDWitkopMRechtMKesslerCBaumannKHernandezGWangMCooperDLKemptonCL.Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study.Eur J Haematol2018;100:5–13
39.
Al-HunitiAReyes HernandezMTen EyckPStaberJM.Mental health disorders in haemophilia: systematic literature review and meta-analysis.Haemophilia2020;26:431–42
40.
CroteauSEChengDCohenAJHolmesCEMalecLMSilveyMThornburgCDWheelerAPKouidesPARaffiniLJNeufeldEJ. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S.Haemophilia2019;25:668–75
41.
GuhSGrosseSDMcAlisterSKesslerCMSoucieJM.Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008.Haemophilia2012;18:268–75
42.
GuhSGrosseSDMcAlisterSKesslerCMSoucieJM.Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008.Haemophilia2012;18:276–83
43.
ShresthaAEldar-LissaiAHouNLakdawallaDNBattK.Real-world resource use and costs of haemophilia A-related bleeding.Haemophilia2017;23:e267–75
44.
ZhouZYKoerperMAJohnsonKARiskeBBakerJRUllmanMCurtisRGPoonJLLouMNicholMB.Burden of illness: direct and indirect costs among persons with hemophilia A in the United States.J Med Econ2015;18:457–65
45.
BolousNSChenYWangHDavidoffAMDevidasMJacobsTWMeagherMMNathwaniACNeufeldEJPirasBARodriguez-GalindoCReissUMBhaktaN.The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective.Blood2021;138:1677–90
46.
CookKForbesSPAdamskiKMaJJChawlaAGarrisonLPJr.Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A.J Med Econ2020;23:501–12
47.
MachinNRagniMVSmithKJ.Gene therapy in hemophilia A: a cost-effectiveness analysis.Blood Adv2018;2:1792–8
WrightJF.Codon modification and PAMPs in clinical AAV vectors: the tortoise or the hare?Mol Ther2020;28:701–3
53.
KlamrothRHayesGAndreevaTGreggKSuzukiTMithaIHHardestyBShimaMPollockTSlevPOldenburgJOzeloMCStieltjesNCastetSMMahlanguJPeyvandiFKazmiRSchvedJFLeavittADCallaghanMPan-PeteschBQuonDVAndrewsJTrinhALiMWongWY.Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A.Hum Gene Ther2022;33:432–41
54.
MannoCSPierceGFArrudaVRGladerBRagniMRaskoJJOzeloMCHootsKBlattPKonkleBDakeMKayeRRazaviMZajkoAZehnderJRustagiPKNakaiHChewALeonardDWrightJFLessardRRSommerJMTiggesMSabatinoDLukAJiangHMingozziFCoutoLErtlHCHighKAKayMA.Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.Nat Med2006;12:342–7
55.
LongBRVeronPKurandaKHardetRMitchellNHayesGMWongWYLauKLiMHockMBZoogSJVettermannCMingozziFSchweighardtB.Early phase clinical immunogenicity of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A.Mol Ther2021;29:597–610
56.
MajowiczANijmeijerBLampenMHSpronckLde HaanMPetryHvan DeventerSJMeyerCTangelderMFerreiraV.Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs.Mol Ther Methods Clin Dev2019;14:27–36
57.
WeberT.Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions.Front Immunol2021;12:658399
MonahanPENegrierCTarantinoMValentinoLAMingozziF.Emerging immunogenicity and genotoxicity considerations of adeno-associated virus vector gene therapy for hemophilia.J Clin Med2021;10:2471
60.
DalwadiDACalabriaATiyaboonchaiAPoseyJNauglerWEMontiniEGrompeM.AAV integration in human hepatocytes.Mol Ther2021;29:2898–909
61.
OrlowskiAKatzMGGubaraSMFargnoliASFishKMWeberT.Successful transduction with AAV vectors after selective depletion of anti-AAV antibodies by immunoadsorption.Mol Ther Methods Clin Dev2020;16:192–203
62.
ChicoineLGMontgomeryCLBremerWGShontzKMGriffinDAHellerKNLewisSMalikVGroseWEShillingCJCampbellKJPrestonTJColeyBDMartinPTWalkerCMClarkKRSahenkZMendellJRRodino-KlapacLR.Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery.Mol Ther2014;22:338–47
63.
LeborgneCBarbonEAlexanderJMHanbyHDelignatSCohenDMCollaudFMuraleetharanSLupoDSilverbergJHuangKvan WittengergheLMarolleauBMirandaAFabianoADaventureVBeckHAnguelaXMRonzittiGArmourSMLacroix-DesmazesSMingozziF.IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies.Nat Med2020;26: 1096–101
64.
MauroVPChappellSA.A critical analysis of codon optimization in human therapeutics.Trends Mol Med2014;20:604–13
65.
PittmanDDMarquetteKAKaufmanRJ.Role of the B domain for factor VIII and factor V expression and function.Blood1994;84:4214–25
66.
Samelson-JonesBJSullivanSKRaskoJEJGiermaszAGeorgeLADucoreJMTeitelJMMcGuinnCEO’BrienAWinburnISmithLMChhabraARuponJ.Follow-up of more than 5 years in a cohort of patients with hemophilia B treated with fidanacogene elaparvovec adeno-associated virus gene therapy.Blood2021;138:3975
67.
DarbySCKeelingDMSpoonerRJWan KanSGiangrandePLCollinsPWHillFGHayCR, UK Haemophilia Centre Doctors’ Organisation. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.J Thromb Haemost2004;2:1047–54
68.
LjungRAuerswaldGBensonGDolanGDuffyAHermansCJiménez-YusteVLambertTMorfiniMZupančić-ŠalekSSantagostinoE.Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.Eur J Haematol2019;102:111–22
69.
HolsteinKLe QuellecSKlamrothRBatorovaAHolmePAJiménez-YusteVAstermarkJ.Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors.Haemophilia2022;28:215–22
70.
FinnJDOzeloMCSabatinoDEFranckHWMerricksEPCrudeleJMZhouSKazazianHHLillicrapDNicholsTCArrudaVR.Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.Blood2010;116:5842–8
71.
SabatinoDELangeAMAltynovaESSarkarRZhouSMerricksEPFranckHGNicholsTCArrudaVRKazazianHHJr.Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.Mol Ther2011;19:442–9
72.
CrudeleJMFinnJDSinerJIMartinNBNiemeyerGPZhouSMingozziFLothropCDJrArrudaVR.AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.Blood2015;125:1553–61
73.
CalcedoRMorizonoHWangLMcCarterRHeJJonesDBatshawMLWilsonJM.Adeno-associated virus antibody profiles in newborns, children, and adolescents.Clin Vaccine Immunol2011;18:1586–8
74.
CantoreANaldiniL.WFH state-of-the-art paper 2020: in vivo lentiviral vector gene therapy for haemophilia.Haemophilia2021;27:122–5
